Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.

M, Schiavoni; M, Napolitano; G, Giuffrida; A, Coluccia; S, Siragusa; V, Calafiore; G, Lassandro; P, Giordano

doi:10.3389/fmed.2019.00261

Public

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.

Shared by NobleBlocks on Dec 3, 2019 • 12:00 AM UTC

Authors:

Schiavoni M

Napolitano M

Giuffrida G

Abstract

The current interest in recombinant factor VIII (rFVIII) products stems from the fact that they offer a technological solution to prolonging the half-life of and reducing the risk of formation of alloantibodies (inhibitors) against FVIII in treated patients with hemophilia A (HA). The Italian health...

Subject

Inhibitors

Pharmacokinetics

Hemophilia A

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!